Suppr超能文献

前瞻性队列研究中血液透析剂量与患者死亡率的关系。

The association between dose of hemodialysis and patients mortality in a prospective cohort study.

机构信息

Department of Nephrology, Dalian Municipal Central Hospital, No.826, Xinan Road, Dalian, Liaoning, 116033, China.

Dalian Key Laboratory of Intelligent Blood Purification, Dalian Municipal Central Hospital, No.826, Xinan Road, Dalian, Liaoning, 116033, China.

出版信息

Sci Rep. 2022 Aug 12;12(1):13708. doi: 10.1038/s41598-022-17943-0.

Abstract

Dialysis adequacy is a known risk factor for mortality in maintenance hemodialysis (MHD) patients. However, the optimal dialysis dose remains controversial. Therefore, we aimed to explore the relationship between dialysis dose and all-cause and cardiovascular disease (CVD) mortality among MHD. We examined the associations of dialysis dose with mortality in a cohort (n = 558) of MHD patients from 31 December 2015 to 31 December 2020. Dialysis adequacy was assessed using baseline Single-pool Kt/V (spKt/V), which was categorized into three groups, and the lowest dose group was used as the reference category. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression models. A total of 214 patients died (64.5% for CVD). Compared with the low-dose group, high-dose group could reduce the risk of all-cause mortality by 33% (HR = 0.67, 95% CI: 0.47-0.98). Of note, when stratification by age, high-dose group was associated with both lower all-cause (HR = 0.46, 95% CI: 0.26-0.81) and CVD mortality (HR = 0.42, 95% CI: 0.20-0.88) among patients with age below 65 years. When stratification by dialysis age, high-dose group was associated with decreased risk of CVD mortality (HR = 0.43, 95% CI: 0.20-0.91) among patients with dialysis age over 60 months. spKt/V is a simple index of hemodialysis dose used in clinical practice and a useful modifiable factor in predicting the risk of death, especially in MHD patients under 65 years old or dialysis age more than 60 months.

摘要

透析充分性是维持性血液透析(MHD)患者死亡的已知危险因素。然而,最佳透析剂量仍存在争议。因此,我们旨在探讨 MHD 患者透析剂量与全因和心血管疾病(CVD)死亡率之间的关系。我们检查了透析剂量与 2015 年 12 月 31 日至 2020 年 12 月 31 日期间的 558 例 MHD 患者队列中死亡率的关系。透析充分性使用基线单池 Kt/V(spKt/V)评估,分为三组,最低剂量组为参考类别。使用 Cox 比例风险回归模型计算风险比(HR)和 95%置信区间(CI)。共有 214 名患者死亡(64.5%为 CVD)。与低剂量组相比,高剂量组可降低 33%的全因死亡率风险(HR=0.67,95%CI:0.47-0.98)。值得注意的是,按年龄分层时,高剂量组与年龄低于 65 岁的患者全因(HR=0.46,95%CI:0.26-0.81)和 CVD 死亡率(HR=0.42,95%CI:0.20-0.88)均呈负相关。按透析年龄分层时,高剂量组与透析年龄超过 60 个月的患者 CVD 死亡率降低相关(HR=0.43,95%CI:0.20-0.91)。spKt/V 是临床实践中使用的血液透析剂量的简单指标,是预测死亡风险的有用可改变因素,尤其是在年龄低于 65 岁或透析年龄超过 60 个月的 MHD 患者中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/010f/9374660/6c36c058d555/41598_2022_17943_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验